MARKET

PCVX

PCVX

Vaxcyte, Inc.
NASDAQ
47.46
+0.17
+0.36%
After Hours: 46.90 -0.56 -1.18% 19:03 06/12 EDT
OPEN
47.30
PREV CLOSE
47.29
HIGH
48.44
LOW
46.71
VOLUME
1.03M
TURNOVER
--
52 WEEK HIGH
65.00
52 WEEK LOW
29.08
MARKET CAP
6.85B
P/E (TTM)
-6.8859
1D
5D
1M
3M
1Y
5Y
1D
Did Vaxcyte’s (PCVX) First-in-Human Strep Vaccine Trial Just Reframe Its Pipeline Ambitions?
Simply Wall St · 23h ago
S&P 500 Futures Fall In Premarket Trading; Super Micro Computer, XPO Lag
Dow Jones · 3d ago
Weekly Report: what happened at PCVX last week (0601-0605)?
Weekly Report · 5d ago
Vaxcyte (PCVX) Valuation Check As VAX A1 Begins Phase 1 Group A Strep Trial
Simply Wall St · 5d ago
Does Vaxcyte’s First-in-Human Group A Strep Trial Reshape The Bull Case For Vaxcyte (PCVX)?
Simply Wall St · 06/04 22:25
Vaxcyte COO Jim Wassil disposes of common shares worth $111,467.81
PUBT · 06/03 20:59
Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), Vaxcyte (PCVX) and BeOne Medicines (ONC)
TipRanks · 06/03 18:00
Vaxcyte (PCVX) Has a New Rating from Mizuho Securities
TipRanks · 06/03 00:16
More
About PCVX
Vaxcyte, Inc. is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company's pipeline includes VAX-31, VAX-24 and VAX-XL. VAX-31, a 31-valent PCV candidate being evaluated in the OPUS Phase III adult clinical program and in a Phase II infant clinical program, is being developed for the prevention of IPD and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-XL leverages the Company’s carrier-sparing, site-specific conjugation technology. It is re-engineering the way highly complex vaccines are made through XpressCF, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella.

Webull offers Vaxcyte Inc stock information, including NASDAQ: PCVX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCVX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PCVX stock methods without spending real money on the virtual paper trading platform.